CenTNF monoclonal antibody that blocks tumor necrosis factor data

Researchers presented positive data from a randomized, double-blind, placebo-controlled trial of 108 patients with the disease. As presented at the American Gastroenterology Association meeting in San Francisco, patients received a single iv infusion of 5, 10 or 20 mg/kg of CenTNF or placebo. Disease activity was followed for 12 weeks, with data presentation focused on the four-week point. Data for the treatment groups was combined.

At four weeks after treatment, >65 percent of treated patients had significant improvement in disease activity, defined as a 70 point reduction on the Crohn's disease activity index (CDAI), versus 17 percent of the placebo group (p<0.001). The median reduction was 107 points for treated patients. At four weeks, 33 percent of the treated group had clinical remissions, defined as <150 points on the CDAI, versus 4 percent of placebo patients. Baseline CDAI scores ranged from 220-400. ...